

Northwestern University Institutional Biosafety Committee

Meeting Minutes

Date: 7/16/2025 11:00 AM

Called to Order: 11:00 AM

Adjourned: 11:50 AM

Location: 345 E Superior St, Suite 1522, Chicago, IL 60611

Northwestern University conducts some or all of its IBC meetings via teleconference (either Zoom or Microsoft Teams, as Northwestern policy requires). A public meeting notice was posted; no comments or attendance requests were received. Attendees of a Northwestern IBC meeting are reminded of confidentiality and conflict of interest expectations. A public meeting notice was posted on the Research Safety website and no public comment was received.

IBC Members

Please see the NIH Office of Science Policy Registration Management System for official Committee Members' roles.

Name	Committee Role	Attendance
Mary Hummel	Chair	Present
Greg Smith	Chair	Present
Gregory Beitel	Member	Present
Jennifer Brace	Member	-
Jacob Class	Member	Present
Alexis Demonbreun	Member	Present
Adriana Ferreira	Member	Present
Robert Foreman	Member	Present
Susan Fox	Member	Present
Lucy Godley	Member	-
Erica Hartmann	Member	Present
Sydni Hill	Member	Present
Robert Holmgren	Member	Present
Changhwa Hwang	Member	Present
Sarah Kopp	Member	Present
Maciej Lesniak	Member	-
Stephen Levin	Member	Present
Liming Li	Member	Present
Emma Liechty	Member	-
Narsa Machireddy	Member	-
Michael McRaven	Member	Present
Jeremy T Ritzert	Member	-
Irina Shepotinovskaya	Member	-
Suchitra Swaminathan	Member	-
Clyde Yancy	Member	-
Nicolette Zielinski-Mozny	Member	Present
Robert Birkett	Alternate	Present

Name	Committee Role	Attendance
Crista Brawley	Alternate	-
Jane Cullen	Alternate	-
Mandy Kozlowski	Alternate	-
Alicia McLuckie	Alternate	Present
Marina Zelivyanskaya	Alternate	Present
James Zewe	Alternate	Present
Michael Hantak	Administrator	Present
Iwona Spath	Administrator	Present

Registrations for Full-Committee Review

Research Group	Principal Investigator	Submission Type
Arispe Lab	Luisa Arispe	De Novo Review
Chiu (Stephen) Lab	Stephen Chiu	Initial Protocol
Amendment for BIO20220031	Francesca Duncan	Amendment
Amendment for BIO20220017	Nayereh Ghoreishi	Amendment
Center For Innovations in Global Health Technologies (CIGHT)	Matthew Glucksberg	De Novo Review
Servin-Vences Lab	Rocio Servin-Vences	Initial Protocol
Zelano Lab	Christina Zelano	De Novo Review

Approval of Previous Meeting Minutes

Previous Meeting Date: 6/18/25

Determination: Approve

Comments: Smith made a motion to approve the meeting minutes. Hummel seconded the motion. The Committee unanimously supported the motion.

Meeting Minutes

Review of Arispe Lab

De Novo Review

Principal Investigator	Luisa Arispe
Submission ID	BIO20250079
Applicable NIH Guidelines	<ul style="list-style-type: none">• Section III-D-1-a• Section III-E-3• Section III-D-4-b• Section III-F-8-C-I• Section III-D-4-a• Section III-D-4• Section III-F• Section III-E• Section III-D-2-a• Section III-F-8-C-II• Section III-F-1• Section III-D-1• Section III-F-8-C-VII• Section III-D-4-c-(2)• Section III-D-2• Section III-D• Section III-D-3• Section III-D-3-a• Section III-F-8-C-VIII• Section III-F-8
Containment Level	BSL-2
Determination	Approve with modifications
Comments	<p>The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.</p> <p>Training for the PI and all applicable lab personnel was current at the time the submission was approved.</p> <p>Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.</p> <p>The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.</p> <p>The Primary Reviewer made a motion to approve this submission with minor modifications.</p> <p>The Committee unanimously supported the motion.</p>

Review of Chiu Lab

Initial Protocol

Principal Investigator	Stephen Chiu
Submission ID	BIO20250008
Applicable NIH Guidelines	<ul style="list-style-type: none">• Section III-E-3• Section III-D-4• Section III-F• Section III-E• Section III-F-1• Section III-D• Section III-F-8
Containment Level	BSL-2
Determination	Approve
Comments	<p>The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.</p> <p>Training for the PI and all applicable lab personnel was current at the time the submission was approved.</p> <p>Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.</p> <p>The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.</p> <p>The Primary Reviewer made a motion to approve this submission.</p> <p>The Committee unanimously supported the motion.</p>

Review of Amendment for BIO20220031

Amendment

Principal Investigator	Francesca Duncan
Submission ID	BIO20220031-AM0002
Applicable NIH Guidelines	<ul style="list-style-type: none">• Section III-E-3• Section III-D-3-d• Section III-F• Section III-E• Section III-F-1• Section III-D-1• Section III-F-8-C-VII• Section III-D• Section III-F-8
Containment Level	BSL-2
Determination	Approve
Comments	<p>The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.</p> <p>Training for the PI and all applicable lab personnel was current at the time the submission was approved.</p> <p>Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.</p> <p>The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.</p> <p>The Primary Reviewer made a motion to approve this submission.</p> <p>The Committee unanimously supported the motion.</p>

Review of Amendment for BIO20220017

Amendment

Principal Investigator	Nayereh Ghoreishi
Submission ID	BIO20220017-AM0016
Applicable NIH Guidelines	<ul style="list-style-type: none">• Section III-D-4-b• Section III-D-4• Section III-D-4-c-(1)• Section III-F• Section III-D-1• Section III-F-8-C-VII• Section III-D-4-c-(2)• Section III-D• Section III-F-8-C-VIII• Section III-F-8
Containment Level	BSL-2
Determination	Approve
Comments	<p>The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.</p> <p>Training for the PI and all applicable lab personnel was current at the time the submission was approved.</p> <p>Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.</p> <p>The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.</p> <p>The Primary Reviewer made a motion to approve this submission.</p> <p>The Committee unanimously supported the motion.</p>

Review of Center For Innovations in Global Health Technologies (CIGHT)

De Novo Review

Principal Investigator	Matthew Glucksberg
Submission ID	BIO20250040
Applicable NIH Guidelines	<ul style="list-style-type: none">• Section III-F• Section III-F-1• Section III-F-8
Containment Level	BSL-2+
Determination	Approve
Comments	<p>The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.</p> <p>Training for the PI and all applicable lab personnel was current at the time the submission was approved.</p> <p>Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.</p> <p>The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.</p> <p>The Primary Reviewer made a motion to approve this submission.</p> <p>The Committee unanimously supported the motion.</p>

Review of Servin-Vences Lab

Initial Protocol

Principal Investigator	Rocio Servin-Vences
Submission ID	BIO20250059
Applicable NIH Guidelines	<ul style="list-style-type: none">• Section III-E-3• Section III-D-4-b• Section III-D-4• Section III-D-1• Section III-F-8-C-VII• Section III-D-4-c-(2)• Section III-F-8
Containment Level	BSL-2
Determination	Approve with modifications
Comments	<p>The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.</p> <p>Training for the PI and all applicable lab personnel was current at the time the submission was approved.</p> <p>Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.</p> <p>The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.</p> <p>The Primary Reviewer made a motion to approve this submission with minor modifications.</p> <p>The Committee unanimously supported the motion.</p>

Review of Zelano Lab

De Novo Review

Principal Investigator	Christina Zelano
Submission ID	BIO20250058
Applicable NIH Guidelines	<ul style="list-style-type: none">• Section III-F• Section III-F-1
Containment Level	BSL-2+
Determination	Approve
Comments	<p>The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.</p> <p>Training for the PI and all applicable lab personnel was current at the time the submission was approved.</p> <p>Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.</p> <p>The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.</p> <p>The Primary Reviewer made a motion to approve this submission.</p> <p>The Committee unanimously supported the motion.</p>

Administratively-Approved Exempt Registrations and Amendments

Genomics Lab

Initial Protocol

Principal Investigator	Hiam Abdala-Valencia
Submission ID	BIO20250056
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-F• Section III-F-1
Containment Level	BSL-1
Approval Date	7/2/2025

Continuing Review for BIO20220037

Continuing Review

Principal Investigator	Sarki Abdulkadir
Submission ID	BIO20220037-CR0002
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-D-1-a• Section III-D-4• Section III-D-2-a• Section III-F-1• Section III-D-1• Section III-D-2• Section III-D• Section III-D-3• Section III-F-8
Containment Level	BSL-2
Approval Date	6/30/2025

CAM - Center for Advanced Microscopy

Initial Protocol

Principal Investigator	Constadina Arvanitis
Submission ID	BIO20250066
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-F-2• Section III-F• Section III-F-1• Section III-D-1• Section III-D• Section III-D-3• Section III-F-8
Containment Level	BSL-2+
Approval Date	7/1/2025

Continuing Review for BIO20240060**Continuing Review**

Principal Investigator	Shana Augustin
Submission ID	BIO20240060-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-E-3• Section III-D-4-b• Section III-D-4-a• Section III-F• Section III-E• Section III-F-1• Section III-D-1• Section III-F-8-C-VII• Section III-D-4-c-(2)• Section III-D• Section III-F-8-C-VIII• Section III-F-8
Containment Level	BSL-2
Approval Date	6/30/2025

Continuing Review for BIO20240045**Continuing Review**

Principal Investigator	Rajeshwar Awatramani
Submission ID	BIO20240045-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-E-3• Section III-D-4-b• Section III-D-4-a• Section III-F• Section III-E• Section III-F-1• Section III-D-1• Section III-F-8-C-VII• Section III-D-4-c-(2)• Section III-D• Section III-F-8-C-VIII• Section III-F-8
Containment Level	BSL-2
Approval Date	6/20/2025

Continuing Review for BIO20230018**Continuing Review**

Principal Investigator	Cecelia Berin
Submission ID	BIO20230018-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-F• Section III-F-1
Containment Level	BSL-2
Approval Date	6/27/2025

Continuing Review for BIO20220122**Continuing Review**

Principal Investigator	Brenda Bohnsack
Submission ID	BIO20220122-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-D-4-a• Section III-D-4• Section III-F• Section III-F-1• Section III-D-2• Section III-D• Section III-F-8
Containment Level	BSL-2
Approval Date	6/27/2025

Continuing Review for BIO20240001**Continuing Review**

Principal Investigator	Rex Chisolm
Submission ID	BIO20240001-CR0002
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-F-1• Section III-F-8
Containment Level	BSL-2
Approval Date	6/30/2025

Amendment for BIO20240107**Amendment**

Principal Investigator	Insup Choi
Submission ID	BIO20240107-AM0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-D-4-b• Section III-D-4-a• Section III-D-4• Section III-D-4-c-(1)• Section III-F• Section III-F-1• Section III-D-4-c-(2)• Section III-D• Section III-D-4-c• Section III-F-8
Containment Level	BSL-2
Approval Date	6/27/2025

Amendment for BIO20230112**Amendment**

Principal Investigator	Yingzi Cong
Submission ID	BIO20230112-AM0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-E-3• Section III-D-4• Section III-F-1
Containment Level	BSL-2
Approval Date	6/20/2025

Continuing Review for BIO20230016**Continuing Review**

Principal Investigator	Kathleen Green
Submission ID	BIO20230016-CR0001
Applicable NIH Guidelines covering the entire registration	
Containment Level	BSL-2
Approval Date	7/2/2025

Amendment/CR for BIO20240039**Amendment/CR**

Principal Investigator	SeungHye Han
Submission ID	BIO20240039-AMCR0002
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-E-3• Section III-D-7• Section III-E-3-a• Section III-D-4• Section III-D-4-c-(1)• Section III-F• Section III-F-1• Section III-F-8-C-VII• Section III-D-4-c-(2)• Section III-D• Section III-D-3• Section III-D-3-a• Section III-F-8
Containment Level	BSL-2
Approval Date	7/15/2025

Amendment for BIO20240034**Amendment**

Principal Investigator	Brandon Jutras
Submission ID	BIO20240034-AM0002
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• • Section III-F-2• • Section III-D-4• • Section III-F• • Section III-E• • Section III-F-8-C-II• • Section III-F-1• • Section III-D-1• • Section III-D-2• • Section III-F-4
Containment Level	BSL-2
Approval Date	6/26/2025

Continuing Review for BIO20240051**Continuing Review**

Principal Investigator	Atsushi Kato
Submission ID	BIO20240051-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-F• Section III-F-1• Section III-F-8
Containment Level	BSL-2+
Approval Date	6/27/2025

Continuing Review for BIO20220130**Continuing Review**

Principal Investigator	David Klumpp
Submission ID	BIO20220130-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-F• Section III-E• Section III-F-8-C-II• Section III-F-1• Section III-F-8-C-VII• Section III-D-2• Section III-D• Section III-F-4
Containment Level	BSL-2
Approval Date	6/20/2025

Continuing Review for BIO20220142**Continuing Review**

Principal Investigator	I. Caroline Le Poole
Submission ID	BIO20220142-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-F-8-C-V• Section III-D-4• Section III-F• Section III-F-8-C-II• Section III-F-1• Section III-D-1• Section III-F-8-C-VII• Section III-D-2• Section III-D• Section III-D-3• Section III-F-8-C-VIII• Section III-F-8
Containment Level	BSL-2
Approval Date	6/10/2025

Continuing Review for BIO20240096**Continuing Review**

Principal Investigator	Aline Martin
Submission ID	BIO20240096-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-D-4• Section III-F• Section III-F-1• Section III-D• Section III-F-8
Containment Level	BSL-2
Approval Date	7/2/2025

Continuing Review for BIO20220074**Continuing Review**

Principal Investigator	Daniela Matei
Submission ID	BIO20220074-CR0003
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-D-4• Section III-F• Section III-F-1• Section III-D-1• Section III-D• Section III-D-3• Section III-F-8
Containment Level	BSL-2
Approval Date	6/20/2025

Continuing Review for BIO20240054**Continuing Review**

Principal Investigator	James Mathew
Submission ID	BIO20240054-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-E-3• Section III-D-4• Section III-F• Section III-E• Section III-D• Section III-F-8
Containment Level	BSL-2
Approval Date	6/27/2025

Continuing Review for BIO20230079**Continuing Review**

Principal Investigator	Joshua Meeks
Submission ID	BIO20230079-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-E-3• Section III-D-4• Section III-F• Section III-E• Section III-F-1• Section III-D-1• Section III-F-8-C-VII• Section III-D-2• Section III-D• Section III-D-3• Section III-F-8
Containment Level	BSL-2
Approval Date	7/2/2025

Amendment for BIO20240043**Amendment**

Principal Investigator	Luisa Morales-Nebreda
Submission ID	BIO20240043-AM0006
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-E-3• Section III-D-7• Section III-D-4• Section III-F-1• Section III-F-8
Containment Level	BSL-2+
Approval Date	6/11/2025

Continuing Review for BIO20230007**Continuing Review**

Principal Investigator	Adam Murphy
Submission ID	BIO20230007-CR0001
Applicable NIH Guidelines covering the entire registration	
Containment Level	BSL-2
Approval Date	7/14/2025

Amendment/CR for BIO20220005**Amendment/CR**

Principal Investigator	Magdalena Osburn
Submission ID	BIO20220005-AMCR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-F• Section III-F-1• Section III-F-8-C-VIII
Containment Level	BSL-1
Approval Date	6/24/2025

Amendment for BIO20230091**Amendment**

Principal Investigator	Saba Parvez
Submission ID	BIO20230091-AM0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-D-4-b• Section III-D-4• Section III-F-8-C-II• Section III-F-1• Section III-D-2• Section III-D
Containment Level	BSL-1
Approval Date	6/27/2025

Amendment for BIO20220045**Amendment**

Principal Investigator	Luis Rosas-Vidal
Submission ID	BIO20220045-AM0001
Applicable NIH Guidelines covering the entire registration	
Containment Level	BSL-2
Approval Date	6/26/2025

Continuing Review for BIO20230080**Continuing Review**

Principal Investigator	Jason Sanchez
Submission ID	BIO20230080-CR0002
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-D-4-b• Section III-D-4• Section III-D
Containment Level	BSL-2
Approval Date	6/20/2025

Amendment for BIO20220020**Amendment**

Principal Investigator	Samuel Stupp
Submission ID	BIO20220020-AM0002
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-D-4• Section III-F• Section III-E• Section III-F-1• Section III-D-1• Section III-D• Section III-D-3• Section III-F-8
Containment Level	BSL-2
Approval Date	6/4/2025

Continuing Review for BIO20240072**Continuing Review**

Principal Investigator	Fred Turek
Submission ID	BIO20240072-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-F• Section III-F-1• Section III-F-8-C-VII• Section III-F-8-C-VIII• Section III-F-8
Containment Level	BSL-1
Approval Date	6/24/2025

Other Agenda Items

Description:	Northwestern IBC program review based upon NIH guidelines (2024 version of reporting tool).
Related Projects:	
Notes:	

Description:	Reminder regarding timely reviews by Committee Members
Related Projects:	
Notes:	

Description:	During a routine lab inspection, it was noted that the Zhao (Youyang) Lab was not storing DT in accordance with their approved IBC registration.
Related Projects:	BIO20240038
Notes:	<p>The BSO presented a description of events to the Committee.</p> <p>Foreman made a motion to require the lab to revise registration to state that the toxin will be stored in a locked box; confirm that all members of the lab have access to the toxin log; provide the IBC with the log monthly (first Monday) for 6 months; LSS will visit twice over 6 months impromptu.</p> <p>Smith seconded the motion.</p> <p>The Committee unanimously supported the motion.</p>

Description:	
Related Projects:	BIO20250018
Notes:	<p>The BSO presented a description of the incident to the Committee and follow up taken by Research Safety.</p> <p>The BSO informed the Committee that the NIH had already been informed of the incident and a response was not received by the time of the meeting.</p> <p>The Committee determined that no further action was required.</p>